SILO — Silo Pharma Inc

Silo Pharma Inc (SILO) is a biotechnology company listed on OTCQB. It is led by Eric Weisblum, based in 677 North Washington Boulevard, Sarasota, FL, United States, 34236, with about 3 employees. Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Latest reported SILO revenue for 2025-09-30 was $18.0K. Net income was -$1.1M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. SILO currently screens at market cap $4.4M.

Use this SILO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SILO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SILO SEC filings page. Lician reads the product cache first so this HTML stays unique to Silo Pharma Inc even when a live quote feed is slow.